Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose–response meta-analysis of 33 randomized controlled trials

Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic contr...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 17; no. 1; pp. 410 - 19
Main Authors Wang, Long, Yang, Hong, Huang, Hao, Zhang, Chao, Zuo, Hong-Xia, Xu, Pan, Niu, Yu-Ming, Wu, Shi-Shi
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 05.12.2019
BioMed Central
BMC
Subjects
Analysis
Bias
Blood glucose
Clinical trials
Diabetes
Diabetes mellitus (non-insulin dependent)
Fasting
Glucose
Glycemic control
Glycosylated hemoglobin
Hemoglobin
Hemoglobins
Homeostasis
Insulin
Insulin resistance
Inulin
Inulin-type fructans supplementation
Laboratory testing
Meta-analysis
Online data bases
Prediabetes
Prediabetic state
Sensitivity analysis
Software
Studies
Supplements
Type 2 diabetes
Glycemic control
Type 2 diabetes
Prediabetes
Inulin-type fructans supplementation
Meta-analysis
Online AccessGet full text
ISSN1479-5876
1479-5876
DOI10.1186/s12967-019-02159-0

Cover

Abstract Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic control. PubMed, EMBASE and the Cochrane Library were searched for eligible articles up to March 6, 2019. A random-effects model was used to analyze the pooled results, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to assess the quality of evidence. The dose-response model was used to recommend the daily dose and duration for ITF supplementation. Thirty-three trials involving 1346 participants were included. Overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR). In the prediabetes and type 2 diabetes (T2DM) population, a more significant reduction in FBG [weighted mean difference (WMD): - 0.60 mmol/l; 95% CI - 0.71, - 0.48 mmol/l; high rate], HbA1c (WMD: - 0.58%; 95% CI - 0.83, - 0.32%; high rate), FINS (WMD: - 1.75 µU/ml; 95% CI - 2.87, - 0.63 µU/ml; low rate), and HOMA-IR (WMD: - 0.69; 95% CI - 1.10, - 0.28; low rate) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended. Moreover, subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF. Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population. Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management. Trial registration The trial was registered at PROSPERO as CRD42018115875 on November 23, 2018.
AbstractList Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic control. PubMed, EMBASE and the Cochrane Library were searched for eligible articles up to March 6, 2019. A random-effects model was used to analyze the pooled results, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to assess the quality of evidence. The dose-response model was used to recommend the daily dose and duration for ITF supplementation. Thirty-three trials involving 1346 participants were included. Overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR). In the prediabetes and type 2 diabetes (T2DM) population, a more significant reduction in FBG [weighted mean difference (WMD): - 0.60 mmol/l; 95% CI - 0.71, - 0.48 mmol/l; high rate], HbA1c (WMD: - 0.58%; 95% CI - 0.83, - 0.32%; high rate), FINS (WMD: - 1.75 µU/ml; 95% CI - 2.87, - 0.63 µU/ml; low rate), and HOMA-IR (WMD: - 0.69; 95% CI - 1.10, - 0.28; low rate) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended. Moreover, subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF. Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population. Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management. Trial registration The trial was registered at PROSPERO as CRD42018115875 on November 23, 2018.
Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic control.BACKGROUNDCurrently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic control.PubMed, EMBASE and the Cochrane Library were searched for eligible articles up to March 6, 2019. A random-effects model was used to analyze the pooled results, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to assess the quality of evidence. The dose-response model was used to recommend the daily dose and duration for ITF supplementation.METHODSPubMed, EMBASE and the Cochrane Library were searched for eligible articles up to March 6, 2019. A random-effects model was used to analyze the pooled results, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to assess the quality of evidence. The dose-response model was used to recommend the daily dose and duration for ITF supplementation.Thirty-three trials involving 1346 participants were included. Overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR). In the prediabetes and type 2 diabetes (T2DM) population, a more significant reduction in FBG [weighted mean difference (WMD): - 0.60 mmol/l; 95% CI - 0.71, - 0.48 mmol/l; high rate], HbA1c (WMD: - 0.58%; 95% CI - 0.83, - 0.32%; high rate), FINS (WMD: - 1.75 µU/ml; 95% CI - 2.87, - 0.63 µU/ml; low rate), and HOMA-IR (WMD: - 0.69; 95% CI - 1.10, - 0.28; low rate) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended. Moreover, subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF.RESULTSThirty-three trials involving 1346 participants were included. Overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR). In the prediabetes and type 2 diabetes (T2DM) population, a more significant reduction in FBG [weighted mean difference (WMD): - 0.60 mmol/l; 95% CI - 0.71, - 0.48 mmol/l; high rate], HbA1c (WMD: - 0.58%; 95% CI - 0.83, - 0.32%; high rate), FINS (WMD: - 1.75 µU/ml; 95% CI - 2.87, - 0.63 µU/ml; low rate), and HOMA-IR (WMD: - 0.69; 95% CI - 1.10, - 0.28; low rate) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended. Moreover, subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF.Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population. Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management. Trial registration The trial was registered at PROSPERO as CRD42018115875 on November 23, 2018.CONCLUSIONSOur analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population. Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management. Trial registration The trial was registered at PROSPERO as CRD42018115875 on November 23, 2018.
Background Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic control. Methods PubMed, EMBASE and the Cochrane Library were searched for eligible articles up to March 6, 2019. A random-effects model was used to analyze the pooled results, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to assess the quality of evidence. The dose-response model was used to recommend the daily dose and duration for ITF supplementation. Results Thirty-three trials involving 1346 participants were included. Overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR). In the prediabetes and type 2 diabetes (T2DM) population, a more significant reduction in FBG [weighted mean difference (WMD): - 0.60 mmol/l; 95% CI - 0.71, - 0.48 mmol/l; high rate], HbA1c (WMD: - 0.58%; 95% CI - 0.83, - 0.32%; high rate), FINS (WMD: - 1.75 [micro]U/ml; 95% CI - 2.87, - 0.63 [micro]U/ml; low rate), and HOMA-IR (WMD: - 0.69; 95% CI - 1.10, - 0.28; low rate) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended. Moreover, subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF. Conclusions Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population. Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management. Trial registration The trial was registered at PROSPERO as CRD42018115875 on November 23, 2018. Keywords: Inulin-type fructans supplementation, Glycemic control, Type 2 diabetes, Prediabetes, Meta-analysis
Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic control. PubMed, EMBASE and the Cochrane Library were searched for eligible articles up to March 6, 2019. A random-effects model was used to analyze the pooled results, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to assess the quality of evidence. The dose-response model was used to recommend the daily dose and duration for ITF supplementation. Thirty-three trials involving 1346 participants were included. Overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR). In the prediabetes and type 2 diabetes (T2DM) population, a more significant reduction in FBG [weighted mean difference (WMD): - 0.60 mmol/l; 95% CI - 0.71, - 0.48 mmol/l; high rate], HbA1c (WMD: - 0.58%; 95% CI - 0.83, - 0.32%; high rate), FINS (WMD: - 1.75 [micro]U/ml; 95% CI - 2.87, - 0.63 [micro]U/ml; low rate), and HOMA-IR (WMD: - 0.69; 95% CI - 1.10, - 0.28; low rate) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended. Moreover, subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF. Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population. Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management.
Background Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic control. Methods PubMed, EMBASE and the Cochrane Library were searched for eligible articles up to March 6, 2019. A random-effects model was used to analyze the pooled results, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to assess the quality of evidence. The dose–response model was used to recommend the daily dose and duration for ITF supplementation. Results Thirty-three trials involving 1346 participants were included. Overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR). In the prediabetes and type 2 diabetes (T2DM) population, a more significant reduction in FBG [weighted mean difference (WMD): − 0.60 mmol/l; 95% CI − 0.71, − 0.48 mmol/l; high rate], HbA1c (WMD: − 0.58%; 95% CI − 0.83, − 0.32%; high rate), FINS (WMD: − 1.75 µU/ml; 95% CI − 2.87, − 0.63 µU/ml; low rate), and HOMA-IR (WMD: − 0.69; 95% CI − 1.10, − 0.28; low rate) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended. Moreover, subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF. Conclusions Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population. Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management. Trial registration The trial was registered at PROSPERO as CRD42018115875 on November 23, 2018.
Abstract Background Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are inconclusive. The aim of this meta-analysis of randomized controlled trials was to assess the effects of ITF supplementation on glycemic control. Methods PubMed, EMBASE and the Cochrane Library were searched for eligible articles up to March 6, 2019. A random-effects model was used to analyze the pooled results, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was applied to assess the quality of evidence. The dose–response model was used to recommend the daily dose and duration for ITF supplementation. Results Thirty-three trials involving 1346 participants were included. Overall, ITF supplementation could significantly reduce concentrations of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), fasting insulin (FINS) and homeostasis model assessment-insulin resistance (HOMA-IR). In the prediabetes and type 2 diabetes (T2DM) population, a more significant reduction in FBG [weighted mean difference (WMD): − 0.60 mmol/l; 95% CI − 0.71, − 0.48 mmol/l; high rate], HbA1c (WMD: − 0.58%; 95% CI − 0.83, − 0.32%; high rate), FINS (WMD: − 1.75 µU/ml; 95% CI − 2.87, − 0.63 µU/ml; low rate), and HOMA-IR (WMD: − 0.69; 95% CI − 1.10, − 0.28; low rate) were observed, and ITF supplementation with a daily dose of 10 g for a duration of 6 weeks and longer was recommended. Moreover, subgroup analyses suggested that the effects of glycemic control were significantly influenced by the sex of the subjects and the type and the method of intake of ITF. Conclusions Our analyses confirmed that these four main glycemic indicators were significantly reduced by ITF supplementation, particularly in the prediabetes and T2DM population. Evidence supports that reasonable administration of ITF supplementation may have potential clinical value as an adjuvant therapy for prediabetes and T2DM management. Trial registration The trial was registered at PROSPERO as CRD42018115875 on November 23, 2018.
ArticleNumber 410
Audience Academic
Author Wang, Long
Yang, Hong
Zhang, Chao
Wu, Shi-Shi
Huang, Hao
Xu, Pan
Zuo, Hong-Xia
Niu, Yu-Ming
Author_xml – sequence: 1
  givenname: Long
  surname: Wang
  fullname: Wang, Long
– sequence: 2
  givenname: Hong
  surname: Yang
  fullname: Yang, Hong
– sequence: 3
  givenname: Hao
  surname: Huang
  fullname: Huang, Hao
– sequence: 4
  givenname: Chao
  surname: Zhang
  fullname: Zhang, Chao
– sequence: 5
  givenname: Hong-Xia
  surname: Zuo
  fullname: Zuo, Hong-Xia
– sequence: 6
  givenname: Pan
  surname: Xu
  fullname: Xu, Pan
– sequence: 7
  givenname: Yu-Ming
  surname: Niu
  fullname: Niu, Yu-Ming
– sequence: 8
  givenname: Shi-Shi
  orcidid: 0000-0001-6625-2540
  surname: Wu
  fullname: Wu, Shi-Shi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31805963$$D View this record in MEDLINE/PubMed
BookMark eNp9k81u1DAQgCNURH_gBTggS1y4pDi2YzsckKpSSqVKSAjOluPYW6-cONhJ0XLiHXhDTjwGs7tt6VYIJYot55vPGWfmsNgb4mCL4nmFj6tK8te5Ig0XJa6aEpOqhuej4qBioilrKfjevfl-cZjzEmPCatY8KfZpJXHdcHpQ_L4Y5uCHclqNFrk0m0kPGeV5HIPt7TDpyccB-X5M8dpmtAgrY3tvkInDlGJALiY0XVk0Jtt53doJID10aOMj6G5tjOMcNrL8BiWb5zBl2C_2SKPzTyfvzkqds4W7Q3mVJ9sDawC89vbbRtjFbH_9-AmhIzgs6u2kSz3osMo-o-gQpSgBGHv_HSQ33xdgOiWvQ35aPHYw2Gc341Hx5f3Z59MP5eXH84vTk8vS1JxOpaMdZp1gQghnqZGyY5K0tLW0paZyXUUd7homMJVEmAZjJ4GXTGhRW641PSoutt4u6qUak-91WqmovdosxLRQOkFuwSrCsGWk1dRJxixzrZHctFxIQg3jBIPr7dY1zm1vOwP_I-mwI919M_grtYjXisuG84aB4NWNIMWvs82T6n02NgQ92DhnRSghgmEhakBfPkCXcU5wvhtKCkxwTf9SCw0J-MFF2NespeqEY9E0gkkO1PE_KLi6de1AETsP6zsBL-4nepfhbZ0CILeASTHnZJ0yflubYPZBVVitW0JtW0JBS6hNS6j1IZIHobf2_wT9AWErFFg
CitedBy_id crossref_primary_10_3390_nu14102096
crossref_primary_10_3390_nu13082748
crossref_primary_10_47836_pjtas_47_2_11
crossref_primary_10_3390_foods11233934
crossref_primary_10_1186_s12906_023_03847_7
crossref_primary_10_1155_2021_5579369
crossref_primary_10_1055_a_1624_5095
crossref_primary_10_3390_ph18020279
crossref_primary_10_1128_msphere_00668_24
crossref_primary_10_1055_a_2312_0040
crossref_primary_10_1097_HEP_0000000000000987
crossref_primary_10_1016_j_cdnut_2023_102059
crossref_primary_10_5468_ogs_21185
crossref_primary_10_1080_19490976_2021_2007042
crossref_primary_10_3390_nu14235139
crossref_primary_10_1111_dme_14657
crossref_primary_10_3389_fnut_2023_1108088
crossref_primary_10_1038_s41526_023_00331_x
crossref_primary_10_3389_fnut_2024_1520779
crossref_primary_10_1136_bmjopen_2021_049184
crossref_primary_10_32615_bp_2023_011
crossref_primary_10_1016_j_exger_2020_111095
crossref_primary_10_1134_S0012496623700655
crossref_primary_10_1016_j_bcdf_2023_100349
crossref_primary_10_1007_s11428_022_00908_2
crossref_primary_10_3920_BM2021_0090
crossref_primary_10_1007_s11428_024_01174_0
crossref_primary_10_1055_a_1543_1293
crossref_primary_10_1016_j_dsx_2023_102923
crossref_primary_10_1016_j_jep_2021_114762
crossref_primary_10_3390_antiox11010058
crossref_primary_10_1007_s00217_021_03872_1
crossref_primary_10_3389_fnut_2022_972399
crossref_primary_10_1016_j_clnu_2020_10_032
crossref_primary_10_1136_bmjopen_2021_058875
crossref_primary_10_1210_endrev_bnac004
crossref_primary_10_1055_a_2166_6772
crossref_primary_10_1016_j_ajcnut_2023_12_003
crossref_primary_10_59124_guhes_1399261
crossref_primary_10_1055_a_1997_7924
crossref_primary_10_29413_ABS_2021_6_6_2_2
crossref_primary_10_1155_2024_4222083
crossref_primary_10_3389_fphys_2020_00070
crossref_primary_10_1016_j_jff_2024_106422
crossref_primary_10_1016_j_ajcnut_2023_10_030
crossref_primary_10_1017_gmb_2022_4
crossref_primary_10_3390_plants13071021
crossref_primary_10_1186_s12967_023_04230_3
crossref_primary_10_12677_HJFNS_2020_93030
crossref_primary_10_1111_cen_14712
crossref_primary_10_1007_s11428_023_01041_4
crossref_primary_10_1002_pdi_2285
crossref_primary_10_3390_foods14030491
crossref_primary_10_1055_a_1886_3959
crossref_primary_10_1016_j_beem_2021_101507
crossref_primary_10_1016_j_jnutbio_2023_109401
crossref_primary_10_1017_S0007114524000904
crossref_primary_10_1088_1755_1315_1052_1_012069
crossref_primary_10_1016_j_ajcnut_2023_06_021
crossref_primary_10_1186_s13099_021_00446_0
crossref_primary_10_1002_mnfr_202200531
crossref_primary_10_3390_nu14040823
Cites_doi 10.1111/jgh.13700
10.1016/j.phrs.2016.06.019
10.1016/j.nut.2013.09.005
10.1079/PNS2002213
10.1055/s-0043-119089
10.1186/1475-2891-11-44
10.1016/j.diabres.2007.05.004
10.1093/ajcn/nqz041
10.1155/2016/5190846
10.1007/s00394-017-1409-z
10.2337/dc18-2549
10.1016/j.metabol.2007.03.019
10.3945/ajcn.117.163246
10.1111/j.1753-0407.2010.00099.x
10.1177/1074248414555004
10.1017/S0007114513003607
10.1016/j.clnu.2008.01.015
10.1017/S0007114599001087
10.1038/ejcn.2016.156
10.1186/1471-2288-5-13
10.1136/gutjnl-2012-303304
10.1079/BJN20041350
10.1900/RDS.2014.11.138
10.1016/j.clnu.2015.07.009
10.1053/j.gastro.2017.03.051
10.1097/XEB.0000000000000132
10.4093/dmj.2013.37.2.140
10.1016/j.clnu.2003.07.010
10.1017/S0007114516004086
10.3945/ajcn.2009.27465
10.1007/s00394-018-1721-2
10.1159/000441626
10.1093/jn/130.6.1572
10.1016/j.jclinepi.2010.04.026
10.1002/mnfr.201601006
10.1007/s11745-014-3901-z
10.1177/2047487317709554
10.3109/09637486.2013.836738
10.1007/s00394-013-0648-x
10.1093/ije/dyv083
10.1038/sj.ejcn.1602127
10.3747/pdi.2014.00015
10.1016/j.ctim.2015.12.010
10.1016/j.cell.2018.09.004
10.2337/dc14-1203
10.1080/10408398.2017.1355775
10.1111/jhn.12251
10.1111/nure.12076
10.3945/jn.112.166132
10.1016/j.pcd.2014.02.004
10.1007/s11010-013-1911-4
10.1186/s12986-015-0033-2
10.1093/ajcn/63.6.939
10.1016/j.jclinepi.2010.07.015
10.15171/apb.2018.005
10.15171/mejdd.2017.66
10.1186/1479-5868-11-2
10.2174/138161210790883570
10.1093/ajcn/69.1.64
ContentType Journal Article
Copyright COPYRIGHT 2019 BioMed Central Ltd.
2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2019
Copyright_xml – notice: COPYRIGHT 2019 BioMed Central Ltd.
– notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2019
DBID AAYXX
CITATION
NPM
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12967-019-02159-0
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 19
ExternalDocumentID oai_doaj_org_article_240e42ba3f844e4fbc86cb67823c4620
PMC6896694
A607997486
31805963
10_1186_s12967_019_02159_0
Genre Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: ;
  grantid: 81872698
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
-A0
3V.
ACRMQ
ADINQ
C24
NPM
PMFND
7T5
7XB
8FK
AZQEC
DWQXO
EJD
H94
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c563t-f3d04d74777fe3c88d482b3be3b3c1fd13f0d94703827c900f804d847a75e6aa3
IEDL.DBID 7X7
ISSN 1479-5876
IngestDate Wed Aug 27 01:24:12 EDT 2025
Thu Aug 21 14:13:45 EDT 2025
Fri Jul 11 04:12:05 EDT 2025
Fri Jul 25 19:59:45 EDT 2025
Tue Jun 17 21:50:52 EDT 2025
Tue Jun 10 20:36:47 EDT 2025
Thu Jan 02 22:58:50 EST 2025
Tue Jul 01 03:51:13 EDT 2025
Thu Apr 24 23:00:59 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Glycemic control
Type 2 diabetes
Prediabetes
Inulin-type fructans supplementation
Meta-analysis
Language English
License Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c563t-f3d04d74777fe3c88d482b3be3b3c1fd13f0d94703827c900f804d847a75e6aa3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ORCID 0000-0001-6625-2540
OpenAccessLink https://www.proquest.com/docview/2328702053?pq-origsite=%requestingapplication%
PMID 31805963
PQID 2328702053
PQPubID 43076
PageCount 19
ParticipantIDs doaj_primary_oai_doaj_org_article_240e42ba3f844e4fbc86cb67823c4620
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6896694
proquest_miscellaneous_2322740775
proquest_journals_2328702053
gale_infotracmisc_A607997486
gale_infotracacademiconefile_A607997486
pubmed_primary_31805963
crossref_citationtrail_10_1186_s12967_019_02159_0
crossref_primary_10_1186_s12967_019_02159_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2019-12-05
PublicationDateYYYYMMDD 2019-12-05
PublicationDate_xml – month: 12
  year: 2019
  text: 2019-12-05
  day: 05
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of translational medicine
PublicationTitleAlternate J Transl Med
PublicationYear 2019
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References P Dehghan (2159_CR29) 2016; 24
P Dehghan (2159_CR31) 2014; 30
AR Tovar (2159_CR51) 2012; 11
H Rajkumar (2159_CR46) 2015; 20
P Dehghan (2159_CR30) 2014; 65
MH Rault-Nania (2159_CR13) 2008; 27
H Shakeri (2159_CR50) 2014; 49
BP Gargari (2159_CR34) 2013; 37
Z Asemi (2159_CR22) 2016; 35
W Ahmed (2159_CR56) 2019; 59
C Cherbut (2159_CR59) 2003; 62
K Chen (2159_CR12) 2017; 61
F Forcheron (2159_CR33) 2007; 56
A Ghavami (2159_CR35) 2018; 8
V Behrouz (2159_CR23) 2017; 9
EM Dewulf (2159_CR32) 2013; 62
J Vulevic (2159_CR53) 2013; 143
G Guyatt (2159_CR19) 2011; 64
AM Kiviniemi (2159_CR4) 2019; 42
X Wang (2159_CR7) 2019; 110
HC Gerstein (2159_CR2) 2007; 78
NKA Bonsu (2159_CR25) 2012; 21
ND Guess (2159_CR38) 2016; 68
SP Hozo (2159_CR16) 2005; 5
FM Silva (2159_CR55) 2013; 71
B Wilson (2159_CR11) 2017; 32
C Pedersen (2159_CR45) 2016; 116
H Balshem (2159_CR20) 2011; 64
MB Roberfroid (2159_CR10) 2005; 93
LW Arnold (2159_CR63) 2014; 11
NK Bonsu (2159_CR15) 2011; 3
MR Bomhof (2159_CR24) 2019; 58
J Luo (2159_CR41) 1996; 63
JA Parnell (2159_CR44) 2009; 89
L Javadi (2159_CR40) 2017; 4
C Xu (2159_CR18) 2018; 16
SM Moosheer (2159_CR6) 2014; 8
H Lightowler (2159_CR9) 2018; 57
2159_CR1
AT Nordestgaard (2159_CR8) 2015; 44
EJ Aguiar (2159_CR5) 2014; 11
J Luo (2159_CR42) 2000; 130
LE Simental-Mendía (2159_CR17) 2016; 111
SV Thompson (2159_CR54) 2017; 106
B Jayashree (2159_CR58) 2014; 388
F Liu (2159_CR14) 2017; 71
EE Canfora (2159_CR26) 2017; 153
F Russo (2159_CR48) 2010; 16
NJ Kellow (2159_CR57) 2014; 111
MM Scheid (2159_CR49) 2014; 53
V Singh (2159_CR61) 2018; 175
DA De Luis (2159_CR28) 2013; 28
N Roshanravan (2159_CR47) 2017; 49
MS Alles (2159_CR21) 1999; 69
M Nordwall (2159_CR62) 2015; 38
A Norhammar (2159_CR3) 2017; 24
R Giacco (2159_CR36) 2004; 23
KG Jackson (2159_CR39) 1999; 82
L Tripkovic (2159_CR52) 2015; 28
S Jafarnejad (2159_CR60) 2016; 2016
ND Guess (2159_CR37) 2015; 12
CA Daubioul (2159_CR27) 2005; 59
K Meksawan (2159_CR43) 2016; 36
References_xml – volume: 32
  start-page: 64
  issue: Suppl 1
  year: 2017
  ident: 2159_CR11
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/jgh.13700
– volume: 111
  start-page: 272
  year: 2016
  ident: 2159_CR17
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2016.06.019
– volume: 30
  start-page: 418
  issue: 4
  year: 2014
  ident: 2159_CR31
  publication-title: Nutrition.
  doi: 10.1016/j.nut.2013.09.005
– volume: 62
  start-page: 95
  issue: 1
  year: 2003
  ident: 2159_CR59
  publication-title: Proc Nutr Soc.
  doi: 10.1079/PNS2002213
– volume: 49
  start-page: 886
  issue: 11
  year: 2017
  ident: 2159_CR47
  publication-title: Horm Metab Res.
  doi: 10.1055/s-0043-119089
– volume: 11
  start-page: 44
  issue: 1
  year: 2012
  ident: 2159_CR51
  publication-title: Nutr J
  doi: 10.1186/1475-2891-11-44
– volume: 78
  start-page: 305
  issue: 3
  year: 2007
  ident: 2159_CR2
  publication-title: Diabetes Res Clin Pract
  doi: 10.1016/j.diabres.2007.05.004
– volume: 110
  start-page: 76
  issue: 1
  year: 2019
  ident: 2159_CR7
  publication-title: Am J Clin Nutr.
  doi: 10.1093/ajcn/nqz041
– volume: 2016
  start-page: 5190846
  year: 2016
  ident: 2159_CR60
  publication-title: J Nutr Metab.
  doi: 10.1155/2016/5190846
– volume: 57
  start-page: 1259
  issue: 3
  year: 2018
  ident: 2159_CR9
  publication-title: Eur J Nutr
  doi: 10.1007/s00394-017-1409-z
– volume: 42
  start-page: 1319
  issue: 7
  year: 2019
  ident: 2159_CR4
  publication-title: Diabetes Care
  doi: 10.2337/dc18-2549
– volume: 56
  start-page: 1093
  issue: 8
  year: 2007
  ident: 2159_CR33
  publication-title: Metabolism.
  doi: 10.1016/j.metabol.2007.03.019
– volume: 106
  start-page: 1514
  issue: 6
  year: 2017
  ident: 2159_CR54
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.117.163246
– volume: 3
  start-page: 58
  issue: 1
  year: 2011
  ident: 2159_CR15
  publication-title: J Diabetes.
  doi: 10.1111/j.1753-0407.2010.00099.x
– volume: 20
  start-page: 289
  issue: 3
  year: 2015
  ident: 2159_CR46
  publication-title: J Cardiovasc Pharmacol Ther.
  doi: 10.1177/1074248414555004
– volume: 111
  start-page: 1147
  issue: 7
  year: 2014
  ident: 2159_CR57
  publication-title: Br J Nutr
  doi: 10.1017/S0007114513003607
– volume: 27
  start-page: 276
  issue: 2
  year: 2008
  ident: 2159_CR13
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2008.01.015
– volume: 82
  start-page: 23
  issue: 1
  year: 1999
  ident: 2159_CR39
  publication-title: Br J Nutr
  doi: 10.1017/S0007114599001087
– volume: 71
  start-page: 9
  issue: 1
  year: 2017
  ident: 2159_CR14
  publication-title: Eur J Clin Nutr
  doi: 10.1038/ejcn.2016.156
– volume: 5
  start-page: 13
  year: 2005
  ident: 2159_CR16
  publication-title: BMC Med Res Methodol
  doi: 10.1186/1471-2288-5-13
– volume: 62
  start-page: 1112
  issue: 8
  year: 2013
  ident: 2159_CR32
  publication-title: Gut
  doi: 10.1136/gutjnl-2012-303304
– volume: 93
  start-page: S13
  issue: Suppl 1
  year: 2005
  ident: 2159_CR10
  publication-title: Br J Nutr
  doi: 10.1079/BJN20041350
– volume: 11
  start-page: 138
  issue: 2
  year: 2014
  ident: 2159_CR63
  publication-title: Rev Diabet Stud.
  doi: 10.1900/RDS.2014.11.138
– volume: 28
  start-page: 78
  issue: 1
  year: 2013
  ident: 2159_CR28
  publication-title: Nutr Hosp
– volume: 35
  start-page: 819
  issue: 4
  year: 2016
  ident: 2159_CR22
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2015.07.009
– volume: 4
  start-page: 131
  issue: 3
  year: 2017
  ident: 2159_CR40
  publication-title: Crescent J Med Biol Sci.
– volume: 153
  start-page: 87
  issue: 1
  year: 2017
  ident: 2159_CR26
  publication-title: Gastroenterology.
  doi: 10.1053/j.gastro.2017.03.051
– volume: 16
  start-page: 138
  issue: 3
  year: 2018
  ident: 2159_CR18
  publication-title: Int J Evid Based Healthc.
  doi: 10.1097/XEB.0000000000000132
– volume: 37
  start-page: 140
  issue: 2
  year: 2013
  ident: 2159_CR34
  publication-title: Diabetes Metab J.
  doi: 10.4093/dmj.2013.37.2.140
– volume: 23
  start-page: 331
  issue: 3
  year: 2004
  ident: 2159_CR36
  publication-title: Clin Nutr
  doi: 10.1016/j.clnu.2003.07.010
– volume: 21
  start-page: 80
  issue: 3
  year: 2012
  ident: 2159_CR25
  publication-title: Diabetes Metab.
– volume: 116
  start-page: 1869
  issue: 11
  year: 2016
  ident: 2159_CR45
  publication-title: Br J Nutr.
  doi: 10.1017/S0007114516004086
– volume: 89
  start-page: 1751
  issue: 6
  year: 2009
  ident: 2159_CR44
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.2009.27465
– volume: 58
  start-page: 1735
  issue: 4
  year: 2019
  ident: 2159_CR24
  publication-title: Eur J Nutr
  doi: 10.1007/s00394-018-1721-2
– volume: 68
  start-page: 26
  issue: 1
  year: 2016
  ident: 2159_CR38
  publication-title: Ann Nutr Metab
  doi: 10.1159/000441626
– volume: 130
  start-page: 1572
  issue: 6
  year: 2000
  ident: 2159_CR42
  publication-title: J Nutr
  doi: 10.1093/jn/130.6.1572
– volume: 64
  start-page: 383
  issue: 4
  year: 2011
  ident: 2159_CR19
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2010.04.026
– volume: 61
  start-page: 1601006
  issue: 8
  year: 2017
  ident: 2159_CR12
  publication-title: Mol Nutr Food Res
  doi: 10.1002/mnfr.201601006
– volume: 49
  start-page: 695
  issue: 7
  year: 2014
  ident: 2159_CR50
  publication-title: Lipids.
  doi: 10.1007/s11745-014-3901-z
– volume: 24
  start-page: 52
  issue: 3_suppl
  year: 2017
  ident: 2159_CR3
  publication-title: Eur J Prev Cardiol.
  doi: 10.1177/2047487317709554
– volume: 65
  start-page: 117
  issue: 1
  year: 2014
  ident: 2159_CR30
  publication-title: Int J Food Sci Nutr
  doi: 10.3109/09637486.2013.836738
– volume: 53
  start-page: 1457
  issue: 7
  year: 2014
  ident: 2159_CR49
  publication-title: Eur J Nutr
  doi: 10.1007/s00394-013-0648-x
– volume: 44
  start-page: 551
  issue: 2
  year: 2015
  ident: 2159_CR8
  publication-title: Int J Epidemiol
  doi: 10.1093/ije/dyv083
– volume: 59
  start-page: 723
  issue: 5
  year: 2005
  ident: 2159_CR27
  publication-title: Eur J Clin Nutr
  doi: 10.1038/sj.ejcn.1602127
– volume: 36
  start-page: 60
  issue: 1
  year: 2016
  ident: 2159_CR43
  publication-title: Perit Dial Int
  doi: 10.3747/pdi.2014.00015
– volume: 24
  start-page: 96
  year: 2016
  ident: 2159_CR29
  publication-title: Complement Ther Med.
  doi: 10.1016/j.ctim.2015.12.010
– volume: 175
  start-page: 679
  issue: 3
  year: 2018
  ident: 2159_CR61
  publication-title: Cell
  doi: 10.1016/j.cell.2018.09.004
– ident: 2159_CR1
– volume: 38
  start-page: 308
  issue: 2
  year: 2015
  ident: 2159_CR62
  publication-title: Diabetes Care
  doi: 10.2337/dc14-1203
– volume: 59
  start-page: 1
  issue: 1
  year: 2019
  ident: 2159_CR56
  publication-title: Crit Rev Food Sci Nutr
  doi: 10.1080/10408398.2017.1355775
– volume: 28
  start-page: 476
  issue: 5
  year: 2015
  ident: 2159_CR52
  publication-title: J Hum Nutr Diet.
  doi: 10.1111/jhn.12251
– volume: 71
  start-page: 790
  issue: 12
  year: 2013
  ident: 2159_CR55
  publication-title: Nutr Rev
  doi: 10.1111/nure.12076
– volume: 143
  start-page: 324
  issue: 3
  year: 2013
  ident: 2159_CR53
  publication-title: J Nutr
  doi: 10.3945/jn.112.166132
– volume: 8
  start-page: 308
  issue: 4
  year: 2014
  ident: 2159_CR6
  publication-title: Prim Care Diabetes.
  doi: 10.1016/j.pcd.2014.02.004
– volume: 388
  start-page: 203
  issue: 1–2
  year: 2014
  ident: 2159_CR58
  publication-title: Mol Cell Biochem
  doi: 10.1007/s11010-013-1911-4
– volume: 12
  start-page: 36
  issue: 1
  year: 2015
  ident: 2159_CR37
  publication-title: Nutr Metab.
  doi: 10.1186/s12986-015-0033-2
– volume: 63
  start-page: 939
  issue: 6
  year: 1996
  ident: 2159_CR41
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/63.6.939
– volume: 64
  start-page: 401
  issue: 4
  year: 2011
  ident: 2159_CR20
  publication-title: J Clin Epidemiol
  doi: 10.1016/j.jclinepi.2010.07.015
– volume: 8
  start-page: 39
  issue: 1
  year: 2018
  ident: 2159_CR35
  publication-title: Adv Pharm Bull.
  doi: 10.15171/apb.2018.005
– volume: 9
  start-page: 151
  issue: 3
  year: 2017
  ident: 2159_CR23
  publication-title: Middle East J Dig Dis.
  doi: 10.15171/mejdd.2017.66
– volume: 11
  start-page: 2
  year: 2014
  ident: 2159_CR5
  publication-title: Int J Behav Nutr Phys Act.
  doi: 10.1186/1479-5868-11-2
– volume: 16
  start-page: 825
  issue: 7
  year: 2010
  ident: 2159_CR48
  publication-title: Curr Pharm Des
  doi: 10.2174/138161210790883570
– volume: 69
  start-page: 64
  issue: 1
  year: 1999
  ident: 2159_CR21
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/69.1.64
SSID ssj0024549
Score 2.5024567
SecondaryResourceType review_article
Snippet Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the results are...
Background Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control; nevertheless, the...
Abstract Background Currently, many clinical trials have shown that inulin-type fructans (ITF) supplementation is associated with glycemic control;...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 410
SubjectTerms Analysis
Bias
Blood glucose
Clinical trials
Diabetes
Diabetes mellitus (non-insulin dependent)
Fasting
Glucose
Glycemic control
Glycosylated hemoglobin
Hemoglobin
Hemoglobins
Homeostasis
Insulin
Insulin resistance
Inulin
Inulin-type fructans supplementation
Laboratory testing
Meta-analysis
Online data bases
Prediabetes
Prediabetic state
Sensitivity analysis
Software
Studies
Supplements
Type 2 diabetes
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA6yB_Eivm1dpQTBgzTb08mk095WcV2F9SAu7C3kqQOzPcP0zEFP_gf_oSd_hlXph9MIevEyDJ0HSedLPdKVrxh76oI0McxtXilf50Jan9dqJnMbBDobuObG0N3hs_fy9Fy8u5hf7KX6opiwjh64e3FHqHGCKK3hUQkRRLROSWdRxJbcCVkmbx113uBMDSx76PYMV2SUPGpRq0kKsaxz0nH4O1FDia3_T5m8p5SmAZN7GujkBrvem45w3A35JrsSmlvs6ln_cfw2-_m2obDynE5VIRItLKohaCltZxciTmsAi3SKEFr4tPziKDIe-mh1QPMV0ByE9SYMJ7JgGg-pvxLGZ-sx51f7AtBb3y23LdA1FTDw5gOubG7Sl-Tg4TdPNHR3ZFKHftWGH9--b7rw3ACXYWty07OjwCoC54Aq1K8uF1-xk358S_ybcoy0d9j5yeuPr07zPpFD7uaSb_PIfSE8Oi5VFQN3SnmhSstt4Ja7WfQzHgtfCxQ-qqxcXRRRYX3Um6aaI5YMv8sOmlUT7jOwsvDGIJCk4iIaY2dGIjjQELSSFy5mbDasq3Y9yzkl21jq5O0oqTssaMSCTljQRcaej23WHcfHX2u_JLiMNYmfOz1A1OoetfpfqM3YMwKbJimCw3OmvwyBkyQ-Ln0si6pGV0_JjB1OauLud9PiAa66lz6tRisZxXCJ8jVjT8ZiakkRdU1Y7VKdshJEgJixex26xymhnKesTNi6muB-MudpSbP4nLjJpUL_uRYP_sdLesiulbRlKXhofsgOtptdeIQm4NY-Trv9F3hWXyQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1baxQxFA61gvgi3l1bJYLgg4zOTrKZjCBSxVqF9UFc6FvItV3Yzqw7u9D65H_wH_rkz_CczKUdLH1ZlslJSCbfuWVOziHkufVCBz8xSS5dkXBhXFLIsUiM5-BswJ5rjXeHp1_FwYx_OZwcbpGu3FH7AutLXTusJzVbLV6d_jh7Bwz_NjK8FK9r0FkCAyiLBDUY_F4j10Ez5cioUy7Pc--BM9RdnLm030A5xRz-_0vqC6pqGEZ5QS_t3ya3WoOS7jUIuEO2fHmX3Ji2n8zvkb-fSww2T_CslQZMFgvKidZYzLMJHMedofN4tuBrerQ4sxgvT9sYdgpGLQUjkS5Xvjunpbp0NI6X0f7Zsq8EVr-h4MNvFuua4uUVqumnb7DfiY7fl72j59mjaXNzJg7oqtr_-fV71QTtenri1zrRbc4UWgXKGAXF6qqT-U8YpJ3fAv7GyiP1fTLb__j9w0HSlndI7ESwdRKYS7kDdybPg2dWSsdlZpjxzDA7Dm7MQuoKDiJJZrkt0jRIoAdtqvMJIEyzB2S7rEr_iFAjUqc1wEtIxoPWZqyF0QzMQyNYasOIjLt9VbbNfY4lOBYq-kBSqAYLCrCgIhZUOiIv-z7LJvPHldTvES49JWbtjg-q1ZFqhYAC68nzDCYWJOeeB2OlsAbMhYxZLjIY5AWCTSHaYXpWt1ckYJGYpUvtiTQvwAGUYkR2B5QgE-ywuYOr6lhKge0MwjkDqTsiz_pm7IlxdqWvNpEmyzmmRRyRhw26-yWB9MdaTdA7H-B-sOZhSzk_jhnLhQSvuuCPr57WDrmZITNisNBkl2yvVxv_BEy-tXka-fgfZS9aHQ
  priority: 102
  providerName: Scholars Portal
Title Inulin-type fructans supplementation improves glycemic control for the prediabetes and type 2 diabetes populations: results from a GRADE-assessed systematic review and dose–response meta-analysis of 33 randomized controlled trials
URI https://www.ncbi.nlm.nih.gov/pubmed/31805963
https://www.proquest.com/docview/2328702053
https://www.proquest.com/docview/2322740775
https://pubmed.ncbi.nlm.nih.gov/PMC6896694
https://doaj.org/article/240e42ba3f844e4fbc86cb67823c4620
Volume 17
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bixMxFA66C-KLeLe6lgiCDzLsdJJmMr7IVnZdhS5SXCi-DLnuFroztdM-6JP_wX_okz_DczJpu4OwL2GYXEjIl3PLyTmEvDZOKO-GOsmlLRIutE0KORCJdhyUDdhzpfDt8PhMnJ7zz9PhNBrcmuhWuaGJgVDb2qCN_BA4P0ArA8y8X3xPMGsU3q7GFBq3yT6GLkOXrny6U7g4KD-bhzJSHDbA2wQ6WhYJcjooO8woxOz_nzJfY01dt8lrfOjkPrkXBUh61O74A3LLVQ_JnXG8In9E_n6q0Lk8Qdsq9RgcFpgRbTB5Z-sojjtBZ8GW4Bp6Mf9h0D-eRp91CkIsBaGQLpZuY5elqrI0jJfR7b_FNvNX846Czr6erxqKj1Wooh8nsL-JCvfJztJdtGjavpQJA9q6cX9-_V62TrqOXrmVSlSMkUJrTxmjwEhtfTX7CYPE-c3hM2QaaR6T85Pjrx9Ok5jOITFDwVaJZzblFtSXPPeOGSktl5lm2jHNzMDbAfOpLTiQIJnlpkhTL6E9cE-VDwFRij0he1VduWeEapFapQBOQjLuldIDJbRiIA5qwVLje2Sw2dfSxFjnmHJjXgadR4qyxUIJWCgDFsq0R95u-yzaSB83th4hXLYtMUp3-FEvL8p46EuQlhzPYGJecu6410YKo0E8yJjhIoNB3iDYSqQlMD2j4pMIWCRG5SqPRJoXoPBJ0SMHnZZAA0y3egPXMtKgptydmB55ta3GnuhXV7l6HdpkOccwiD3ytEX3dklA7TE3E_TOO7jvrLlbU80uQ4RyIUGLLvjzm6f1gtzN8DCic9DwgOytlmv3EkS8le6Hc9wn-6Pjsy-TfjCUQDnmEsrJ6Ns_ZItbXQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1baxNBFB5qCuqLeDdadQTFB1m62ZnMzgoirbamtg1SWujbdG5bA-luzCZIffI_-D_8UT75MzxnL0kXoW99CWHnwgznm3OZORdCXlovdOr7JoilSwIujAsS2ROB8RyMDaC51hg7vD8UgyP--bh_vEJ-N7Ew6FbZ8MSSUbvc4h35Okh-gFYEmHk_-RZg1Sh8XW1KaFSw2PXn38FkK97tfAT6voqi7a3DD4OgrioQ2L5gsyBlLuQOtOg4Tj2zUjouI8OMZ4bZXup6LA1dwuEkyCi2SRimEvoDE9dxHzamGcx7jaxyBqZMh6xubg2_HCyz-4G51YTmSLFegDQV6NqZBChb4bcl_soqAf_LggvCsO2oeUHybd8mt2qVlW5UGLtDVnx2l1zfrx_l75G_Oxm6swd4m0tTTEcL4o8WWC60ck1H2tNReXvhC3o6PrfokU9rL3kKajMFNZROpr65CaY6c7ScL6KLb5NFrbHiLZ36Yj6eFRTDY6imnw4AUYEuX7C9o8v81LSKzSkndHnh__z8Na3cgj098zMd6DorC81TyhgF0e3ys9EPmKRe3xj-lrVNivvk6EpI_YB0sjzzjwg1InRaA4CFZDzV2vS0MJqBAmoEC23aJb2GrsrW2dWxyMdYlVaWFKrCggIsqBILKuySN4sxkyq3yKW9NxEui56YF7z8kE9PVc1mFOhnnkewsFRy7nlqrBTWgEISMctFBJO8RrAp5F6wPKvrIAzYJOYBUxsijBMwMaXokrVWT-A6tt3cwFXVXK9QyzPaJS8WzTgSPfkyn8_LPlHMMfFilzys0L3YEsgXrAYFo-MW7lt7brdko69lTnQhwW5P-OPLl_Wc3Bgc7u-pvZ3h7hNyM8KDia5J_TXSmU3n_ikomDPzrD7VlJxcNSP5B5zKlKI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inulin-type+fructans+supplementation+improves+glycemic+control+for+the+prediabetes+and+type+2+diabetes+populations%3A+results+from+a+GRADE-assessed+systematic+review+and+dose%E2%80%93response+meta-analysis+of+33+randomized+controlled+trials&rft.jtitle=Journal+of+translational+medicine&rft.au=Wang%2C+Long&rft.au=Yang%2C+Hong&rft.au=Huang%2C+Hao&rft.au=Zhang%2C+Chao&rft.date=2019-12-05&rft.pub=BioMed+Central&rft.eissn=1479-5876&rft.volume=17&rft.spage=1&rft_id=info:doi/10.1186%2Fs12967-019-02159-0
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon